Atara Biotherapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Atara Biotherapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 9, 2026.
NASDAQ
DEFA14A: Atara Biotherapeutics Sets Date for 2025 Annual Meeting, Outlines Proposals for Stockholder Vote
Atara Biotherapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, with key proposals including the election of directors, executive compensation, and ratification of the company's independent auditor.
NASDAQ
Atara Biotherapeutics schedules its 2025 Annual Meeting of Stockholders for June 10, 2025, to address director elections, executive compensation, and auditor ratification.
NASDAQ
Atara Biotherapeutics issues a supplement to its proxy statement to clarify voting standards, the treatment of broker non-votes, and correct a scrivener's error for the upcoming 2024 Annual Meeting of Stockholders.
NASDAQ
Atara Biotherapeutics is holding its annual meeting on June 10, 2024, seeking stockholder approval on several key proposals, including director elections, executive compensation, and a potential reverse stock split.
NASDAQ
DEF 14A: Atara Biotherapeutics Seeks Stockholder Approval for Reverse Stock Split and Equity Incentive Plan
Atara Biotherapeutics is asking stockholders to approve a reverse stock split, elect directors, approve executive compensation, ratify the selection of its auditor, and approve its equity incentive plan at the upcoming annual meeting.